Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Wednesday, 21'st Feb 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Wednesday, 14'th Feb 2024
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:16am, Wednesday, 14'th Feb 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
08:51am, Tuesday, 13'th Feb 2024
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
07:00am, Wednesday, 31'st Jan 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
11:46am, Tuesday, 30'th Jan 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:02am, Tuesday, 16'th Jan 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
12:47pm, Thursday, 11'th Jan 2024
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
03:02pm, Tuesday, 19'th Dec 2023
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:01am, Thursday, 14'th Dec 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos shares jump on FDA approval of iDose TR eye implant
08:57am, Thursday, 14'th Dec 2023
Glaukos shares rose more than 7% in Thursday premarket trading after the company announced US Food and Drug Administration (FDA) approval for iDose TR (travoprost intracameral implant). The iDose TR i
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:02am, Wednesday, 15'th Nov 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
12:02pm, Thursday, 02'nd Nov 2023
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript
11:04pm, Wednesday, 01'st Nov 2023
Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - Ch
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:17pm, Wednesday, 01'st Nov 2023
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Str
